Untitled

The U.S. Food and Drug Administration’s (FDA) Division of Drug Information* presents…”FDA Drug Topics: CURE ID: Capturing Clinician’s Experiences Repurposing Drugs to Inform Future Studies in the Era of COVID-19″

This series of educational webinars is designed to aid physicians, physician assistants, nurses, pharmacists, pharmacy technicians, certified public health professionals, other health care professionals, and students, to provide better patient care by knowing how to find relevant FDA regulatory information that will improve drug safety. This webinar will demonstrate CURE ID – a mobile app and web platform developed by FDA and NCATS/NIH, that gives the global clinical community the opportunity to report novel uses of existing drugs for patients with difficult-to-treat infectious diseases, including COVID-19. The webinar will also explain the features and goals of the platform.

Series Objectives:

• Explain how to utilize FDA’s drug information, medication safety resources, and regulatory guidance, to improve delivery of patient care and optimize outcomes.
• Describe and inform health care providers of recent labeling changes which would impact prescribing and medication management to optimize patient care.

Learning Objectives: After completion of this activity, the participant will be able to:

1. Discuss the intent behind CURE ID.
2. Demonstrate the mobile app and its features.
3. Explain the potential uses of CURE ID.
4. Summarize the limitations of CURE ID.

Target Audience: This activity is intended for physicians, physician assistants, nurses, pharmacists, pharmacy technicians, certified public health professionals, other health care professionals, and students.

Schedule:1:00 pm – 2:00 pm – FDA Drug Topics: CURE ID: Capturing Clinician’s Experiences Repurposing Drugs to Inform Future Studies in the Era of COVID-19 presented by Heather Stone, MPH, Health Science Policy Analyst in FDA’s, Center for Drug Evaluation and Research, Office of Medical Policy.

In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

CME: FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians and physician assistants should claim only the credit commensurate with the extent of their participation in the activity.

CPE: This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-19-020-L04-P, and ACPE Universal Activity Number JA0002895-0000-19-020-L04-T for 1.00 contact hour(s).

CNE: FDA Center for Drug Evaluation and Research designates this activity for 1.00 contact hour(s).

AAPA: This activity is designated for 1.00 AAPA Category 1 CME credits. FDA Center for Drug Evaluation and Research has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. PAs should only claim credit commensurate with the extent of their participation.

CPH: Up to 1.00 CPH Recertification Credits may be earned at this event.

Requirements for receiving CE Credit: Physicians, physician assistants, nurses, pharmacists, pharmacy technicians, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation survey via the CE Portal (ceportal.fda.gov). Final activity evaluations must be completed within two weeks after the activity – no exceptions.

Pharmacy participants: Pharmacists and pharmacy technicians will need their NABP e-profile ID number as well as their DOB in MMDD format in order to claim CE credit.

Important Note regarding completion of evaluations and receiving credit:

Attendees have 14 days from the last day of the activity to log in, attest to your attendance, and complete the required evaluation survey, to claim credit. Physicians and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 10 weeks after the activity to obtain their CE credit.

Disclosure:

Faculty:

• Stone, Heather, MPH, Health Science Policy Analyst, FDA/CDER/OMP – may reference off-label use.

Planning Committee:

• Burke, Kara, PharmD, Team Leader/Pharmacist, FDA/CDER/OCOMM/DDI – nothing to disclose
• Cao, Christian, MPAS, PA-C, Safety Evaluator Team Leader, FDA/CDER/OSE/DPV – nothing to disclose
• DeFronzo, Kimberly, RPh, MS, MBA, Consumer Safety Officer, FDA/CDER/OCOMM/DDI – nothing to disclose
• Kapoor, Rama, MD, Medical Officer, FDA – nothing to disclose
• Navin, Lesley, RN, MSN, Consumer Safety Officer, FDA/CDER/OCOMM/DDI – nothing to disclose

CE Consultation and Accreditation Team:

• Thompson, Lisa, MSHA, MBA, CE Consultant, FDA/CDER/OEP/DLOD – nothing to disclose
• Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD – nothing to disclose

Registration Fees and Refunds: Registration is complimentary therefore refunds are not applicable.

Please direct your comments or questions via email  |   DDIWebinars@fda.hhs.gov.

To learn more about future dates and registration, please visit: www.fda.gov/DDIWebinars. 

*NOTE: This is an industry resource-sponsored webinar. HealthTrust has not approved and/or endorsed the content. This program may contain the mention of products, services, drugs or brands presented in a case study or comparative format. Such examples are intended for educational and informational purposes and should not be perceived as a HealthTrust endorsement of any particular supplier, product, service, drug, brand or approach